EVER vs SLQT vs LMND vs GOCO

For growth investors, Lemonade, Inc.

(LMND) is the stronger pick with 40. 2% revenue growth year-over-year, versus 8. 7% for GoHealth, Inc. (GOCO). EverQuote, Inc. (EVER) offers the better valuation at 7. 8x trailing P/E (10. 4x forward), making it the more compelling value choice. Analysts rate EverQuote, Inc. (EVER) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, EverQuote, Inc.

(EVER) is the cheapest at 7. 8x versus SelectQuote, Inc. at 85. 7x.

Over the past 5 years, Lemonade, Inc.

(LMND) delivered a total return of -31. 2%, compared to -99. 4% for GoHealth, Inc. (GOCO). Over 10 years, the gap is even starker: EVER returned +16. 0% versus GOCO's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), EverQuote, Inc.

(EVER) is the lower-risk stock at 1. 25β versus Lemonade, Inc. 's 2. 75β — meaning LMND is approximately 121% more volatile than EVER relative to the S&P 500. On balance sheet safety, EverQuote, Inc. (EVER) carries a lower debt/equity ratio of 1% versus 115% for GoHealth, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Lemonade, Inc.

(LMND) is pulling ahead at 40. 2% versus 8. 7% for GoHealth, Inc. (GOCO). On earnings-per-share growth, the picture is similar: EverQuote, Inc. grew EPS 198. 9% year-over-year, compared to 19. 3% for Lemonade, Inc.. Over a 3-year CAGR, LMND leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

EverQuote, Inc.

(EVER) is the more profitable company, earning 14. 3% net margin versus -22. 4% for Lemonade, Inc. — meaning it keeps 14. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EVER leads at 9. 6% versus -21. 8% for LMND. At the gross margin level — before operating expenses — EVER leads at 97. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SLQT: 250.

9% to $4. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, EverQuote, Inc.

(EVER) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 25)). GoHealth, Inc. (GOCO) carries a higher beta of 2. 23 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EVER: +16. 0%, GOCO: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EVER (Communication Services) and SLQT (Financial Services) and LMND (Financial Services) and GOCO (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EVER is a small-cap high-growth stock; SLQT is a small-cap high-growth stock; LMND is a small-cap high-growth stock; GOCO is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.